登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06888674,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) post-surgery;
入选标准第 18 条
Contraception agreement: Fertile males and females of childbearing potential must agree to use effective contraception from signing the ICF until 6 months after the last dose of study treatment. Females of childbearing potential include premenopausal women and women ≤2 years postmenopausal;
入选标准第 12 条
Serum CA 19-9 level >180 U/mL within 21 days prior to initiating standard postoperative adjuvant therapy;
排除标准第 1 条
ECOG Performance Status score of 0 or 1;
入选标准第 6 条
ECOG Performance Status score:Cohort A: 0 or 1;Cohort B: 0-2;
入选标准第 20 条
Liver function: Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN;
入选标准第 9 条
Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min (Cockcroft-Gault formula);
入选标准第 10 条
HIV antibody-positive;
排除标准第 10 条
Active hepatitis C (HCV RNA-positive);
排除标准第 12 条
Active hepatitis B (HBsAg-positive and HBV DNA ≥2000 IU/mL);
排除标准第 13 条
Pregnancy or lactation;
排除标准第 24 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06888674,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Pre-Screening Phase Inclusion Criteria (for Radical Surgery and Vaccine Preparation): Subjects meeting all of the following criteria will enter the pre-screening phase for radical surgery and vaccine preparation: Voluntarily sign the informed consent form (ICF); Age ≥18 years, regardless of gender; Diagnosed with resectable pancreatic cancer as assessed per the 2024 NCCN Clinical Practice Guidelines and willing to undergo radical surgery; ECOG Performance Status score of 0 or 1; Ability to obtain sufficient fresh tumor tissue samples for whole-exome sequencing (WES) and transcriptome sequencing analysis; Normal function of major organs (heart, liver, kidneys): Liver function: Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN; Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min (Cockcroft-Gault formula); Cardiac function: LVEF ≥50% by echocardiography; Contraception agreement: Fertile males and females of childbearing potential must agree to use effective contraception from signing the ICF until 6 months after the last dose of study treatment. Females of childbearing potential include premenopausal women and women ≤2 years postmenopausal; Ability to comply with the study protocol and follow-up procedures. Formal Screening Phase Inclusion Criteria (for Study Treatment Initiation): Subjects meeting all of the following criteria will enter the formal screening phase for study treatment: Voluntarily sign the informed consent form (ICF); Age ≥18 years, regardless of gender; Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) post-surgery; Completion of radical resection (R0 or R1) with no evidence of metastatic disease, malignant ascites, or pleural effusion on imaging 4-12 weeks postoperatively; ECOG Performance Status score:Cohort A: 0 or 1;Cohort B: 0-2; Normal function of major organs (heart, liver, kidneys): Contraception agreement: Same as pre-screening criteria; Ability to comply with the study protocol and follow-up procedures.排除标准:Exclusion Criteria:
Serum CA 19-9 level >180 U/mL within 21 days prior to initiating standard postoperative adjuvant therapy; History of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation; Concurrent immunosuppressive therapy, defined as regular use of immunosuppressive agents within 4 weeks prior to screening or during the study, including but not limited to: Severe asthma requiring systemic corticosteroids (≥10 mg/day prednisone equivalent); Active autoimmune disease or immunodeficiency (e.g., rheumatoid arthritis, systemic lupus erythematosus); History of primary immunodeficiency; Exceptions: Type 1 diabetes, autoimmune hypothyroidism managed with hormone replacement, vitiligo, or psoriasis not requiring systemic therapy; Active bacterial/fungal infections requiring systemic treatment, or active/latent tuberculosis (confirmed by interferon-gamma release assay or tuberculin skin test); Active viral infections: HIV antibody-positive; Syphilis (TP antibody-positive with RPR/TRUST confirmation); Active hepatitis C (HCV RNA-positive); Active hepatitis B (HBsAg-positive and HBV DNA ≥2000 IU/mL); Acute viral infections: Herpesvirus infection (unless resolved with crusting >4 weeks prior); Respiratory viral infection (unless resolved >4 weeks prior); Uncontrolled comorbidities: Symptomatic congestive heart failure (NYHA Class III/IV); Unstable angina or arrhythmia requiring treatment; Severe coronary/cerebrovascular disease (e.g., myocardial infarction within 6 months); Other conditions deemed exclusionary by the investigator; History of drug abuse, psychiatric disorders, or psychosocial factors impairing informed consent or protocol compliance; History of severe hypersensitivity to vaccines, biologics, or any component of the study drug; Pregnancy or lactation; Other conditions judged by the investigator to preclude safe participation.
引自 ClinicalTrials.gov, NCT06888674, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06888674,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。